Primary Cells Market worth $2.8 billion | MarketsandMarkets
/PRNewswire/ -- The primary cells industry is poised for significant advancements and growth in the near future. As researchers and pharmaceutical companies...
Stay updated with breaking news from Axol Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The primary cells industry is poised for significant advancements and growth in the near future. As researchers and pharmaceutical companies...
Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.
Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.
Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification. Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell
Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.